EGFR and non-small cell lung carcinoma: Approximately 50% of NSCLC cases develop a secondary point substitution in exon 20 of the EGFR gene (T790M), which confers resistance to first-generation TKI by impeding the inhibition of receptor phosphorylation through a substantially increased affinity of the EGFR’s kinase domain pocket for ATP [125].